USE OF PREDICTORS TO CHOOSE TREATMENT POLICY FOR THYROID CANCER
https://doi.org/10.17650/2222-1468-2014-0-1-11-14
Abstract
The paper analyzes the results of treatment in patients with papillary thyroid cancer, by applying a great deal of clinical material. Different prognostic factors have been studied for their influence on the survival of the patients after surgical treatment. The most optimal treatment policy is proposed to be defined for patients with this form of cancer on the basis of the association between the above factors.
About the Authors
V. Zh. Brzhezovsky,
Research Institute of Clinical Oncology, N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
M. V. Lomaya
Research Institute of Clinical Oncology, N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
T. A. Aketova
Research Institute of Clinical Oncology, N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
References
1. Bilimoria K.Y., Bentrem D.J., Linn J.G. et al. Utilization of total thyroidectomy for papillary thyroid cancer in the United States. Surgery 2007;142(6):906–13 [discussion 913. e1–2].
2. Lin J.D., Chen S.T., Hsueh C., Chao T.C. A 29-year retrospective review of papillary thyroid cancer in one institution. Thyroid 2007 Jun;17(6):535–41.
3. Mazeh H., Samet Y., Hochstein D. et al. Multifocality in well-differentiated thyroid carcinomas calls for total thyroidectomy. Am J Surg 2011 Jun; 201(6):770–5.
4. Ibrahimpasic T., Nixon I.J., Palmer F.L. et al. Undetectable thyroglobulin after total thyroidectomy in patients with lowand intermediate-risk papillary thyroid cancer – is there a need for radioactive iodine therapy? Surgery 2012;152(6):1096–105.
5. Almeida J.P., Sanabria A.E., Lima E.M., Kowalski L. et al. Late side effects of radioactive iodine on salivary gland function in patients with thyroid cancer. Head Neck 2011;33(5):686–90.
6. Nixon I.J., Ganly J., Patel S.G. et al. Thyroid lobectomy for treatment of well differentiated intrathyroid malignancy. Surgery 2012;151(4):571–9.
7. Пачес А.И. Опухоли головы и шеи. Кли- ническое руководство. М., 2013. 475 с.
8. Романчишен А.Ф. Клиническое обосно- вание показаний к оперативному лечению заболеваний щитовидной железы. Вестник хирургии 1994;1–2:3–6.
9. Sosa J.A., Bowman H.M., Tielsch J.M. et al. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg 1998;228(3):320–30.
10. Shah J.P., Loree T.R., Dharker D. et al. Prognostic factors in differentiated carcinoma of the thyroid gland. Am J Surg 1992;164(6):658–61.
11. Nixon I.J., Shah J.P. Well differentiated thyroid cancer: are we over treating our patients? Eur J Surg Oncol 2014 Feb;40(2):129–32.
12. Haymart M.R., Benerjee M., Stewart A.K. et al. Use of radioactive iodine for thyroid cancer. JAMA 2011;306(7):721–8.
13. Trovisco V., Soares P., Sobrinho-Simões M. B-RAF mutations in the etiopathogenesis, diagnosis, and prognosis of thyroid carcinomas. Hum Pathol 2006 Jul;37(7):781–6.
14. Wang W., Zhao W., Wang E.U. et al. Poorer prognosis and higher prevalence of BRAF (V600E) mutation in synchronous bilateral papillary thyroid carcinoma. Ann Surg Oncol 2012 Jan;19(1):31–36.
15. Danilovic D.L., Lima E.U., Domingues R.B. et al. Pre-operative role of BRAF in the guidance of the surgical approach and prognosis of differentiated thyroid carcinoma. Eur J Endocrinol 2014;170(4):619–25.
Review
For citations:
Brzhezovsky, V.Zh., Lomaya M.V., Aketova T.A. USE OF PREDICTORS TO CHOOSE TREATMENT POLICY FOR THYROID CANCER. Head and Neck Tumors (HNT). 2014;(1):11-14. (In Russ.) https://doi.org/10.17650/2222-1468-2014-0-1-11-14
Views:
653
Email this article 